Patient involvement in health technology assessments
There is increasing recognition of the importance of patient involvement in health care decision making, and of the unique contribution that patients can offer through sharing their lived experiences.
The National Centre for Pharmacoeconomics (NCPE) consider that patients can make a valuable contribution to health technology assessment (HTA) of new drug technologies, and to this end have created the patient organisation submission process, which enables patient groups to communicate their experiences directly to the decision maker, the Health Services Executive (HSE).
When new drugs are authorised for use in Ireland, the NCPE conducts a health technology assessment for the HSE to determine the cost effectiveness of the new medicines. The NCPE then makes a recommendation to the HSE as to whether the cost of the drugs should be reimbursed to the pharmaceutical company.
In addition to the clinical and health economic evidence assessed, the NCPE and the HSE want to consider information from patients as part of this decision-making process. In particular, they want to receive information from patients about the day-to-day experience of living with the disease and the ways in which the new drug may improve this day-to-day experience. This information can help the HSE Drugs Committee to understand the real-world impact a new drug may have on the quality of life and daily experience of patients and carers.
When a new drug in rheumatology is being assessed by the NCPE, patients living with the disease for which the drug has been authorised have an opportunity to input into the health technology assessment process. There will be a number of different ways for you to participate; for example, completing a survey, focus group, interview, etc.
If you would like to be part of this, please complete the information in the form below.
Arthritis Ireland will be in touch with you again in due course.
Many thanks for being part of this public and patient involvement (PPI) initiative.